India, Dec. 2 -- Biocon Biologics announced on Tuesday that it has reached a settlement agreement with Amgen Inc., enabling the commercialisation of its Denosumab biosimilars across Europe and other global markets.
Under the agreement, Biocon Biologics will be allowed to launch both biosimilars — Vevzuo and Evfraxy — in Europe beginning December 2, 2025.
The remaining terms of the settlement have not been disclosed.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....